Clinical trials: Advanced Gastric Adenocarcinoma
Adenocarcinoma of Stomach, Adenocarcinoma of GE Junction
Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus
The purpose of this study is to collect information on the anti-tumor activity of the combination doxorubicin, cisplatin, and 5-fluorouracil when given to patients with advanced esophageal or gastric adenocarcinoma.
- Conditions
- Adenocarcinoma of Stomach, Adenocarcinoma of GE Junction, Adenocarcinoma of Esophagus
- Trial name
- NCT00165191
- Testing
- Doxorubicin, Cisplatin, 5-fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Gastric Cancer
Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer
This study is a single-arm, single-center, exploratory clinical study. It is expected that 44 patients with advanced gastric and gastroesophageal junction adenocarcinoma with first-line treatment failure will be included to…
- Trial name
- NCT06499610
- Testing
- Irinotecan Hydrochloride Liposome Injection
- Where
- China
- Volunteers
- 44 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Advanced Gastric Adenocarcinoma, Pancreatic Adenocarcinoma
Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma
A single arm, open-label pilot study is designed to determine the safety, tolerability and engraftment of CAR-CLD18 T cells in patients with advanced gastric adenocarcinoma and pancreatic adenocarcinoma.
- Trial name
- NCT03159819
- Testing
- CAR-CLD18 T Cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Changhai Hospital
Anal Cancer, Anxiety Disorder
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
RATIONALE: Gathering information from patients who received treatment for metastatic cancer while participating in a phase II or phase III randomized clinical trial and from patients receiving standard treatment off-trial may…
- Conditions
- Anal Cancer, Anxiety Disorder, Breast Cancer, Depression
- Trial name
- NCT00896467
- Testing
- questionnaire administration, psychosocial assessment and care, quality-of-life assessment
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Oscar Lambret
Relapsed or Advanced Gastric Adenocarcinoma, Gastro-esophageal Junction Cancer
Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer
This study was planned to evaluate the efficacy and safety of combination therapy of Immuncell-LC and nivolumab in patients with relapsed or advanced gastric adenocarcinoma or gastro-esophageal junction cancer.
- Trial name
- NCT05053295
- Testing
- autologous activated T lymphocyte
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Gangnam Severance Hospital
Gastric Adenocarcinoma, Gastrectomy
PG Versus TG for Advanced PGC
We conducted a retrospective study on patients with pathological stage II-III PGC who underwent PG or TG from 2013 to 2023. Propensity score-matching was applied to adjust for tumor size and stage between the PG and TG groups at…
- Trial name
- NCT06614439
- Testing
- proximal gastrectomy, total gastrectomy
- Where
- Taiwan
- Volunteers
- 96 people
- Sponsor
- National Taiwan University Hospital
Pancreatic Ductal Adenocarcinoma (PDAC), Adenocarcinoma of the Stomach
Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
This was a single-centre, single-arm, non-blinded, prospective study using 20 patients with advanced metastatic GI malignancies recruited to treat patients with advanced metastatic GI malignancies with 177Lu-CTR-FAPI to assess…
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Adenocarcinoma of the Stomach, Colorectal Cancer Metastatic, Neuroendocrine Tumor (NET)
- Trial name
- NCT07014254
- Testing
- 177Lu-CTR-FAPI nuclide-targeted therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xijing Hospital
Breast Cancer, Colorectal Cancer
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00553683
- Testing
- cyclophosphamide, poly ICLC, hepatic artery embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Adenocarcinomas of the Esophagogastric Junction
Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG)
Prospective, single-center, nonrandomized, explorative imaging study evaluating the value of PET as a predictor of histopathological response in metabolic non-responders Patients with resectable AEG (adenocarcinoma of the…
- Trial name
- HICON (NCT01271322)
- Testing
- neoadjuvant radiochemotherapy in metabolic non responders
- Where
- Germany
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Gastric Cancer, Gastroesophageal-junction Cancer
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
The purpose of this study is to evaluate the efficacy of Tislelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ)…
- Trial name
- NCT05687357
- Testing
- Tislelizumab, S-1, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 140 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Malignant Neoplasm of Stomach, Effects of Chemotherapy
Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE
This study investigates the efficacy and safety profiles of sorafenib in combination of capecitabine and cisplatin, one of standard chemotherapy regimens in patients with advanced gastric cancer.
- Trial name
- NCT01187212
- Testing
- Capecitabine/Cisplatin + Sorafenib, Capecitabine/Cisplatin
- Where
- South Korea
- Volunteers
- 195 people
- Sponsor
- Asan Medical Center
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT00544193
- Testing
- gemcitabine hydrochloride, polymerase chain reaction, immunohistochemistry staining method
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Lung Cancer
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
The purpose of this study is to test the combination of an experimental drug known as MGCD0103 given along with an FDA-approved drug called docetaxel.
- Conditions
- Breast Cancer, Lung Cancer, Pulmonary Cancer, Non-Small-Cell Lung Carcinoma
- Trial name
- NCT00511576
- Testing
- MGCD0103 & Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Mirati Therapeutics Inc.
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Advanced Gastric Adenocarcinoma
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy
This study is a single arm, single center phase II study of AZD1775 in combination with paclitaxel in patients with advanced gastric adenocarcinoma harboring TP53 mutation as a second-line chemotherapy.
- Trial name
- NCT02448329
- Testing
- AZD1775, paclitaxel
- Where
- South Korea
- Volunteers
- 26 people
- Sponsor
- Samsung Medical Center
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- LUCERNA (NCT06901531)
- Testing
- zolbetuximab, Pembrolizumab, Capecitabine
- Where
- 253 sites in United States, Australia and 20 more
- Volunteers
- 500 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Gastric Adenocarcinoma
A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma
This study evaluated the tolerance, safety and efficacy of Apatinib plus Docetaxel as the second-line treatment in locally advanced or metastatic gastric cancer (including Gastroesophageal junction (GEJ) Adenocarcinoma).
- Trial name
- NCT03071042
- Testing
- Apatinib, Docetaxel
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sir Run Run Shaw Hospital
Locally Advanced or Metastatic Gastric Adenocarcinoma
Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer
To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate and nab-paclitaxel .
- Trial name
- NCT04572542
- Testing
- Camrelizumab, Apatinib Mesylate, nab-paclitaxel
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
The study evaluated the overall survival (OS) of SHR-A1904 versus investigator-selected treatment in second-line CLDN18.2-positive advanced GC/GEJC patients
- Trial name
- NCT06649292
- Testing
- SHR-A1904, Paclitaxel, Docetaxel, Irinotecan
- Where
- China
- Volunteers
- 524 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.